Skip to main content
Premium Trial:

Request an Annual Quote

Distribution Deals Brings Genaltye Maverick Detection System to Europe

NEW YORK (GenomeWeb News) – Genalyte today announced it has inked distribution deals for its Maverick Detection System covering parts of Europe.

The system, which analyzes multiple antibodies and other proteins, also received the CE Mark for research use in Europe.

San Diego-based Genalyte has reached distribution deals with Mokascience in France; Bucher Biotec in Switzerland; and KRD Molecular Technologies in the Czech Republic, Slovakia, and Hungary. The deals are the firm's first in Europe, it noted.

Financial and other terms of the agreements were not disclosed.

The Maverick Detection System uses a silicon chip with arrays of photonic ring sensors, and its workflow can deliver results in as little as 15 minutes from a small volume of sample of various types, Genalyte said.

Martin Gleeson, CSO of Genalyte, said in a statement that the company plans to launch several multiplex assays in the next few months and to announce additional distribution agreements "as we build a distribution network to reach pharmaceutical, biotechnology, and academic researchers around the globe."

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.